Paper36978391
Disulfiram: Mechanisms, Applications, and Challenges.
Lanz J and 5 others. Antibiotics (Basel), 2023. Cited by 114 papers, by iCite.
Cite this record
ConductScience Library. Disulfiram: Mechanisms, Applications, and Challenges. Papers, record 36978391. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36978391
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References185
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35745663 | Discovery of Triple Inhibitors of Both SARS-CoV-2 Proteases and Human Cathepsin L. | Pharmaceuticals (Basel) | 2022 | https://conductscience.org/library/papers/35745663 | PubMed |
| 2 | 36027862 | Disulfiram and dithiocarbamate analogues demonstrate promising antischistosomal effects. | Eur J Med Chem | 2022 | https://conductscience.org/library/papers/36027862 | PubMed |
| 3 | 35578732 | Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor. | Med Chem Res | 2022 | https://conductscience.org/library/papers/35578732 | PubMed |
| 4 | 9212576 | Psychosis during disulfiram therapy for alcoholism. | J Indian Med Assoc | 1997 | https://conductscience.org/library/papers/9212576 | PubMed |
| 5 | 32364011 | FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication. | J Biomol Struct Dyn | 2021 | https://conductscience.org/library/papers/32364011 | PubMed |
| 6 | 21358812 | Identification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model system. | PLoS Negl Trop Dis | 2011 | https://conductscience.org/library/papers/21358812 | PubMed |
| 7 | 26858599 | The Ubiquitin-Proteasome System: Potential Therapeutic Targets for Alzheimer's Disease and Spinal Cord Injury. | Front Mol Neurosci | 2016 | https://conductscience.org/library/papers/26858599 | PubMed |
| 8 | 23047041 | Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. | Oncotarget | 2012 | https://conductscience.org/library/papers/23047041 | PubMed |
| 9 | 30771200 | A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. | J Neurooncol | 2019 | https://conductscience.org/library/papers/30771200 | PubMed |
| 10 | 6746947 | Spouse contracting to increase antabuse compliance in alcoholic veterans. | J Clin Psychol | 1984 | https://conductscience.org/library/papers/6746947 | PubMed |
| 11 | 4707989 | Disulfiram maintenance in outpatient treatment of alcoholism. | Arch Gen Psychiatry | 1973 | https://conductscience.org/library/papers/4707989 | PubMed |
| 12 | 17075509 | [Optic neuropathy while taking disulfiram]. | J Fr Ophtalmol | 2006 | https://conductscience.org/library/papers/17075509 | PubMed |
| 13 | 35286730 | Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer. | Prostate | 2022 | https://conductscience.org/library/papers/35286730 | PubMed |
| 14 | 27846399 | Sensory-motor axonal polyneuropathy involving cranial nerves: An uncommon manifestation of disulfiram toxicity. | Clin Neurol Neurosurg | 2017 | https://conductscience.org/library/papers/27846399 | PubMed |
| 15 | 31209025 | Borrelia burgdorferi peptidoglycan is a persistent antigen in patients with Lyme arthritis. | Proc Natl Acad Sci U S A | 2019 | https://conductscience.org/library/papers/31209025 | PubMed |
| 16 | 33777846 | Drug Repurposing of the Alcohol Abuse Medication Disulfiram as an Anti-Parasitic Agent. | Front Cell Infect Microbiol | 2021 | https://conductscience.org/library/papers/33777846 | PubMed |
| 17 | 27029711 | Disulfiram neuropathy: two case reports. | J Med Case Rep | 2016 | https://conductscience.org/library/papers/27029711 | PubMed |
| 18 | 26600588 | Disulfiram-induced seizures with convulsions in a young male patient: A case study. | Indian J Psychiatry | 2015 | https://conductscience.org/library/papers/26600588 | PubMed |
| 19 | 34218872 | Devastating Neurological Injury as a Result of Treatment of "Chronic Lyme Disease". | Mayo Clin Proc | 2021 | https://conductscience.org/library/papers/34218872 | PubMed |
| 20 | 8389572 | Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study. | Biotherapy | 1993 | https://conductscience.org/library/papers/8389572 | PubMed |
Cited by74
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 114 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42979729 | Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas. | Mol Oncol | 2026 | https://conductscience.org/library/papers/42979729 | PubMed |
| 42959134 | Anti-obesogenic potential of curcumin, disulfiram, and their synergistic effects in HFD-fed obese Swiss albino mice. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42959134 | PubMed |
| 42797347 | Disulfiram's Anti-Inflammatory and Antibacterial Effects in Fixed-Dose Combination Therapy for Scabies. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42797347 | PubMed |
| 42750843 | Co-treating opioid and alcohol use disorders in the United States, 1960-2026: A historical policy review in the glucagon-like peptide-1 (GLP-1) era. | Drug Alcohol Depend Rep | 2026 | https://conductscience.org/library/papers/42750843 | PubMed |
| 42730929 | Disulfiram reverses fluconazole-resistance mediated by Cdr1 in Candida albicans and interferes with biofilm formation. | Appl Microbiol Biotechnol | 2026 | https://conductscience.org/library/papers/42730929 | PubMed |
| 42662336 | Distinct Effects of Copper Ionophores on Intracellular Copper and Cell Viability in Wild-Type and CTR1-Deficient SH-SY5Y Cells. | ACS Omega | 2026 | https://conductscience.org/library/papers/42662336 | PubMed |
| 42529971 | TrxR Inhibition and Nrf2-FOXO3 Modulation by Repurposed Drugs: A Redox Strategy to Reverse Cancer Multidrug Resistance. | Drug Dev Res | 2026 | https://conductscience.org/library/papers/42529971 | PubMed |
| 42479712 | Bidentate Metal-Binding Motifs in US FDA Approved Small Molecule Drugs. | J Med Chem | 2026 | https://conductscience.org/library/papers/42479712 | PubMed |
| 42435303 | Targeting Copper in Cancer: Chelators to Counteract Cuproplasia and Ionophores to Promote Cuproptosis. | J Med Chem | 2026 | https://conductscience.org/library/papers/42435303 | PubMed |
| 42429921 | Randomized Study About Influence of Food on the Pharmacokinetics of Disulfiram Metabolites in Healthy Individuals. | Eur J Drug Metab Pharmacokinet | 2026 | https://conductscience.org/library/papers/42429921 | PubMed |
| 42367921 | Discovery of cell-active small molecule inhibitors of UDP-galactose 4'-epimerase. | bioRxiv | 2026 | https://conductscience.org/library/papers/42367921 | PubMed |
| 42333434 | Cuproptosis Inducers in Cancer Therapy: State of the Art and Challenges. | Chem Rec | 2026 | https://conductscience.org/library/papers/42333434 | PubMed |
| 42058920 | Off-label and repurposed use of disulfiram beyond alcohol dependence: A systematic review of clinical and preclinical evidence. | iScience | 2026 | https://conductscience.org/library/papers/42058920 | PubMed |
| 41953727 | MYH9: Structure, functions, and therapeutic implications in cancer and genetic disorders. | Genes Dis | 2026 | https://conductscience.org/library/papers/41953727 | PubMed |
| 41918852 | Disulfiram Exhibits Potent Copper-Dependent Antimicrobial Activity Against Mycoplasma genitalium. | Open Forum Infect Dis | 2026 | https://conductscience.org/library/papers/41918852 | PubMed |
| 41915614 | In Vivo Trypanocidal Activity of the Drug Disulfiram Combined with Benznidazole. | ACS Infect Dis | 2026 | https://conductscience.org/library/papers/41915614 | PubMed |
| 41913028 | Cocaine Use Disorder: Neuropathology and Exploratory Treatments. | Mol Neurobiol | 2026 | https://conductscience.org/library/papers/41913028 | PubMed |
| 41828861 | Copper Complexes: Main Mechanisms as Anticancer Agents. | Molecules | 2026 | https://conductscience.org/library/papers/41828861 | PubMed |
| 41777909 | Can disulfiram modulate liver injury in CCl4-induced fibrosis in rats? | Gastroenterol Hepatol Bed Bench | 2025 | https://conductscience.org/library/papers/41777909 | PubMed |
| 41754742 | Disulfiram and Its Derivatives: An Immortal Phoenix of Drug Repurposing. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/41754742 | PubMed |
Genes18
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36978391
GET https://conductscience.org/api/papers/v1/36978391/references?page=2